2017 American Transplant Congress
Tacrolimus Dose Variability, CYP3A5 Genotype, and Acute Rejection in African American and European American Kidney Transplant Recipients.
Background: Poor immunosuppression with tacrolimus (TAC) after kidney transplantation contributes to the development of toxicity and loss of efficacy. We aimed to associate intra-patient TAC…2017 American Transplant Congress
Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial.
While conversion from ciclosporin to everolimus is well documented, conversion from tacrolimus has been poorly studied. In this randomized-controlled trial the safety and tolerability of…2017 American Transplant Congress
Effect of HLA-DQ Mismatch on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients: Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Köln, Germany; 2Novartis Pharma AG, Basel, Switzerland
Purpose: Human leukocyte antigen (HLA)-DQ mismatches are often associated with acute rejection, independent of mismatches at other loci. Previous analysis from the ELEVATE (NCT01114529) study…2017 American Transplant Congress
Early Steroid Withdrawal and Infection in Kidney Transplant Recipients.
Johns Hopkins School of Medicine, Baltimore, MD
One third of kidney transplant (KT) recipients currently undergo early steroid withdrawal (ESW). Although ESW may slightly increase the risk of rejection in certain subgroups,…2017 American Transplant Congress
High Risk Renal Transplant Recipients on Steroid Free Immunosupression Regimen. Indiana University Experience.
Renal Transplant, Indiana University School of Medicine, Indianapolis, IN
Background : Immunologic risk often influence the choice immunosuppressive regimen used in renal transplant recipient. Patient with positive flow cytometry crossmatch (FCXM) or presence of…2017 American Transplant Congress
Clinical Impact of Strength and Class of Pre transplant Donor Specific Antibody on Kidney Transplant Recipient Receiving Steroid Free Maintenance Immunosupression Regimen.
Renal Transplant, Indiana University School of Medicine, Indianapolis, IN
Background: The class and strength of pre- transplant DSA has been described as playing a role in determining future risk of acute rejection (AR) and…2017 American Transplant Congress
Alloimmune Quiescence in Recipients with Long-Term Surviving Kidney Grafts.
Recent studies of tolerant kidney transplant patients have identified increased numbers of circulating B cells expressing an immature/transitional phenotype (IgD+CD27-/IgD+CD27-CD24+CD38+). Similar frequencies of these immature/transitional…2017 American Transplant Congress
Focal Segmental Glomerulosclerosis Recurrence in Renal Transplant Recipients Treated with Belatacept.
Emory Transplant Center, Atlanta, GA
Introduction: Focal segmental glomerulosclerosis (FSGS) is a cause of end-stage renal failure that frequently recurs following renal transplant, often leading to allograft loss. A recently…2017 American Transplant Congress
Conversion from Twice Daily to Once Daily Tacrolimus Improves Adherence in Kidney Transplant Recipients.
INTRODUCITON AND OBJECTIVE: Kidney transplant longevity is largely related to immunosuppressive efficacy, which is highly dependent on patient adherence. Drug dosing frequency is one way…2017 American Transplant Congress
Comparison of Long Term Survival Outcomes for Everolimus (EVR) vs. Mycophenolic Acid (MPA) Immunosuppressive Regimens Post Kidney Transplant.
In the US, MPA in combination with calcineurin inhibitors (CNI, tacrolimus [TAC] or cyclosporine A [CsA]) is the most commonly used maintenance immunosuppressive therapy post…
American Transplant Congress abstracts